Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion ...

Operator Welcome to Globus Medical's third quarter 2024 earnings call. At this time, all lines will be on mute and a Q&A ...

The medical device maker reported big growth in revenue and earnings, driven by strong product sales and a recent major ...

Globus Medical (NYSE:GMED) is up ~8% in after-hours trading Tuesday after raising its 2024 guidance and releasing Q3 ...

JMP Securities analyst David Turkaly has reiterated their neutral stance on GMED stock, giving a Hold rating on November 11. David Turkaly has ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style ...

Amalgamated Bank trimmed its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 5.4% in the third quarter, ...

Globus Medical and NuVasive's merger marked its first year on Sept. 1, Globus' CEO Dan Scavilla said in a Nov. 5 earnings call.

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Globus Medical (GMED) to $100 from $80 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 ...

Globus Medical, Inc.'s ( NYSE:GMED ) recent soft profit numbers didn't appear to worry shareholders, as the stock ...

Globus Medical Inc (GMED) reports a 63% revenue increase and record free cash flow, while addressing FDA concerns and ...